Centre for Clinical Epidemiology and Evaluation, VCHRI, Vancouver, Canada.
Pharmacogenomics J. 2012 Jun;12(3):205-13. doi: 10.1038/tpj.2011.15. Epub 2011 Apr 19.
Cisplatin is a widely used chemotherapy drug in the treatment of pediatric solid tumors, but it is associated with significant rates of ototoxicity (medication-induced hearing loss). A genetic test has recently been developed that can help predict the likelihood that a cisplatin-treated pediatric patient will develop ototoxicity. This study estimates the potential economic impact of this test. Assuming that an alternative, non-preferred, medication to cisplatin exists that it is as efficacious as cisplatin but without the risk of hearing loss, and that the alternative treatment is no more expensive than current practice, we have estimated that administering this genetic test to every pediatric cancer patient for whom cisplatin is first-line therapy could potentially avoid an average of $71,168 in societal costs per tested patient. This translates into a potential present value savings of over $2.4 million annually in British Columbia and over $19.6 million in Canada.
顺铂是一种广泛应用于儿童实体瘤治疗的化疗药物，但它与显著的耳毒性（药物引起的听力损失）相关。最近开发了一种基因检测，可以帮助预测接受顺铂治疗的儿科患者发生耳毒性的可能性。本研究估计了该检测的潜在经济影响。假设存在一种替代的、非首选的、与顺铂同样有效的药物，但没有听力损失的风险，而且替代治疗的费用不高于目前的治疗方法，我们估计，对每一位将顺铂作为一线治疗的儿科癌症患者进行这种基因检测，可能平均为每个接受检测的患者避免 71168 美元的社会成本。这相当于在不列颠哥伦比亚省每年节省潜在的现值超过 240 万美元，在加拿大节省超过 1960 万美元。
